Recognising the major regulatory agencies and knowing which one governs your product
20 min3 quizzes2 drills
Your scenario
A new medical writer joins a global pharma company. Their first week's email traffic mentions a "CHMP opinion" on one project, an "FDA Complete Response Letter" on another, and a "PMDA consultation" scheduled for a third. None of these terms were covered in their onboarding deck. They need a working map of who these bodies are, what each one does, and what kind of document each one produces — before their first team meeting.
Why this matters for a medical writer
You will never be the person deciding which agency reviews a product — that is determined by geography, product class, and company strategy long before a writer is assigned. But you will constantly encounter agency names in emails, timelines, and source documents, and you need to recognise instantly what kind of organisation is being discussed and what it does. This module is a map, not a manual — you are not expected to become a regulatory affairs specialist.
The major regulatory authorities
United States — FDA (Food and Drug Administration): The FDA is organised into centres by product type, and knowing which centre applies tells you a great deal about the pathway a product will follow:
CDER (Center for Drug Evaluation and Research) — reviews small-molecule and most conventional drugs
CBER (Center for Biologics Evaluation and Research) — reviews biologics, vaccines, gene and cell therapies, and blood products
CDRH (Center for Devices and Radiological Health) — reviews medical devices and diagnostic products
European Union — EMA (European Medicines Agency): The EMA coordinates scientific review across the EU through committees, rather than reviewing products itself:
CHMP (Committee for Medicinal Products for Human Use) — the central scientific committee that issues the opinion recommending (or not) marketing authorisation
PRAC (Pharmacovigilance Risk Assessment Committee) — assesses and monitors the safety of medicines
CAT (Committee for Advanced Therapies) — evaluates gene therapies, cell therapies, and tissue-engineered products
Other major national and regional authorities you will encounter:
PMDA (Pharmaceuticals and Medical Devices Agency, Japan) — reviews products for the Japanese market and is known for pre-submission "consultations" with sponsors
CDSCO (Central Drugs Standard Control Organisation, India) — India's national regulatory authority
TGA (Therapeutic Goods Administration, Australia)
Health Canada — Canada's national regulator
NMPA (National Medical Products Administration, China)
What each authority publishes — and why it matters to you
As a writer, the practical value of knowing an authority is knowing what it produces, because these outputs often become source documents or context for your own writing:
Guidance documents: Non-binding recommendations describing how an authority expects a type of study, submission, or analysis to be conducted (e.g., FDA guidance documents, EMA scientific guidelines)
Assessment reports: The EMA publishes EPARs (European Public Assessment Reports) after a decision — a detailed, publicly available account of the scientific review
Approval or refusal letters: The FDA issues an approval letter when a product is authorised, or a Complete Response Letter (CRL) when it identifies deficiencies that must be resolved before approval
Orientation, not memorisation
You do not need to memorise every division of every agency. Know which authority governs your product type — the rest you look up when you need it. This module is designed so that when a name appears in your inbox, you know roughly what kind of body it is and what kind of document to expect from it.
India CDSCO & The New Drugs and Clinical Trials (NDCT) Rules, 2019
For medical writers working in global CROs or Indian biopharma hubs, navigating the Central Drugs Standard Control Organization (CDSCO) requires fluency in the NDCT Rules, 2019:
Subject Expert Committee (SEC): Regulatory dossiers undergo rigorous technical evaluation by disease-specific SEC panels before the Drugs Controller General of India (DCGI) grants approval.
Clinical Trial Approvals: Governed by Form CT-06 (permission to conduct clinical trial for new drug/investigational product) and Form CT-23 (registration of Ethics Committee).
Local Clinical Trial Waivers (Rule 101): Local Phase III clinical trials in Indian patients may be waived if the drug is approved and marketed in specified jurisdictions (US, EU, UK, Japan, Australia, Canada) for unmet medical needs, rare diseases, or pandemic emergencies.
Trial Registration: Mandatory prospective registration on the Clinical Trials Registry - India (CTRI) before enrolling the first participant.
Knowledge check
Which FDA center reviews a monoclonal antibody biosimilar?
A CBER
B CDER
C CDRH
D PRAC
Knowledge check
What does EPAR stand for and who publishes it?
A Early Product Assessment Review, published by the FDA
B European Public Assessment Report, published by the EMA
C European Pharmacovigilance Assessment Record, published by the PMDA
D Extended Product Approval Report, published by CDSCO
Knowledge check
Which regulatory authority is known for a "consultation" process with sponsors before formal submission?
A FDA
B EMA
C PMDA
D TGA
Orientation drill
Match each term to its correct one-line description.
Terms: CHMP, PRAC, CDER, CDRH, Complete Response Letter, Type II Variation
Descriptions to match:
A. FDA centre reviewing conventional small-molecule drugs
B. FDA centre reviewing medical devices
C. EMA committee issuing the scientific opinion on marketing authorisation
D. EMA committee responsible for pharmacovigilance oversight
E. FDA letter identifying deficiencies that must be resolved before approval
F. EU term for a major post-approval change to an existing marketing authorisation
CHMP → C (EMA committee issuing the scientific opinion on marketing authorisation) PRAC → D (EMA committee responsible for pharmacovigilance oversight) CDER → A (FDA centre reviewing conventional small-molecule drugs) CDRH → B (FDA centre reviewing medical devices) Complete Response Letter → E (FDA letter identifying deficiencies that must be resolved before approval) Type II Variation → F (EU term for a major post-approval change to an existing marketing authorisation)
Orientation drill
Your manager asks you to find the EMA's scientific assessment for adalimumab. Write the steps you would take to locate it.
Model steps: 1) Recognise that the document being asked for is an EPAR (European Public Assessment Report) — the EMA's published scientific assessment for an authorised product. 2) Go to the EMA website's medicines database and search by the active substance name ("adalimumab") rather than a brand name, since several branded and biosimilar products may share the same substance. 3) Locate the product's medicine overview page, which links to the full EPAR, including the assessment report, product information, and any subsequent variations. 4) Note that if the product is a biosimilar, there may be a separate EPAR for each biosimilar version, each referencing the originator's data package. 5) Confirm you have the most recent version, since EPARs are updated after each significant post-approval variation.
Reflection
Which regulatory authority's documents are you most likely to encounter in your career? Why?
Consider the therapeutic areas, product types, and markets you expect to work in.
Module 1.1 complete
Drug development lifecycle: where documents live
Week 1 · Module 2
Drug Development Lifecycle: Where Documents Live
Mapping the development timeline so you know which document belongs to which phase
25 min3 quizzes3 drills
Your scenario
A writer is asked to work on "the IB update." They know IB stands for Investigator's Brochure, but they are unsure where it fits in the overall development timeline, who reads it, or why it needs updating at all. Without a mental map of the development lifecycle, this simple request is confusing.
The development pipeline, stage by stage
Drug development follows a broadly predictable sequence, and each stage produces (or updates) a characteristic set of documents:
Discovery → Preclinical: Laboratory and animal studies characterise a candidate's activity, toxicity, and pharmacokinetics. Output: nonclinical study reports.
IND/CTA filing: Before human testing can begin, the sponsor files an IND (Investigational New Drug application) in the US or a CTA (Clinical Trial Application) in the EU and elsewhere. Output: the first Investigator's Brochure (IB) and the first clinical protocol.
Phase I: First-in-human studies, typically focused on safety, tolerability, and dose escalation in a small number of healthy volunteers or patients.
Phase II: Proof-of-concept studies in a larger patient group, exploring efficacy signals and refining dose.
Phase III: Large, confirmatory trials designed to provide the pivotal evidence for regulatory approval.
NDA/MAA submission: The sponsor compiles the full evidence package into an NDA (New Drug Application, US) or MAA (Marketing Authorisation Application, EU).
Regulatory review → Approval: The relevant authority reviews the submission and issues a decision.
Phase IV: Post-marketing studies and ongoing safety monitoring after approval.
Documents produced at each stage
Preclinical: nonclinical study reports
IND/CTA: Investigator's Brochure (IB), first protocol
Phase I–III: protocols, Statistical Analysis Plans (SAPs), Clinical Study Reports (CSRs) for each completed study, Development Safety Update Reports (DSURs), and periodic IB updates
Development phase explorer — documents produced at each stage
Preclinical
IND/CTA
Phase I
Phase II
Phase III
Submission
Post-marketing
Preclinical
Documents: Nonclinical study reports (pharmacology, toxicology, pharmacokinetics).
Purpose: Establish enough safety and rationale to justify testing in humans.
IND / CTA filing
Documents: The first Investigator's Brochure (IB), the first clinical protocol.
Purpose: The IB summarises everything known about the drug so investigators and ethics committees can judge whether the proposed trial is reasonable and safe.
Phase I
Documents: Protocol, SAP, Clinical Study Report (once the study completes), IB update if new safety information emerges.
Purpose: Establish safety, tolerability, and dosing in a small group.
Phase II
Documents: Protocol, SAP, CSR, DSUR (annual safety report while the trial is ongoing), IB updates.
Purpose: Explore efficacy signal and refine the dose for Phase III.
Phase III
Documents: Protocol, SAP, CSR (the pivotal document), continued DSURs, IB updates.
Purpose: Provide the confirmatory evidence of efficacy and safety that will support submission.
Submission (NDA/MAA)
Documents: CTD Module 2 summaries (Clinical Overview, Clinical Summary), the compiled CSRs in Module 5.
Purpose: Synthesise the entire development programme into the structured format regulators expect.
Purpose: Monitor real-world safety once the product is in widespread use.
Orientation point
Notice that the Investigator's Brochure is not a one-time document — it is updated repeatedly across the whole clinical development period as new safety and efficacy information accumulates. This is why "the IB update" can come up at almost any point in a project's life.
Knowledge check
At which development stage is the Clinical Study Report (CSR) first produced?
A During preclinical testing
B Only after Phase III completion
C Only at the time of submission
D After Phase I completion
Knowledge check
The Investigator's Brochure must be updated at least:
A Annually, per ICH E6
B Monthly
C Only once, at IND/CTA filing
D Only at the time of submission
Knowledge check
Which document is submitted to regulatory authorities to initiate a clinical trial in the EU?
A Investigational New Drug application (IND)
B Clinical Trial Application (CTA)
C Marketing Authorisation Application (MAA)
D Development Safety Update Report (DSUR)
Orientation drill
Place the following 8 documents in chronological order along the development timeline.
Documents: Marketing Authorisation Application, first Investigator's Brochure, nonclinical study report, Phase III Clinical Study Report, Phase I Clinical Study Report, first-in-human protocol, PBRER, Clinical Overview (CTD 2.5)
1. Nonclinical study report 2. First Investigator's Brochure 3. First-in-human protocol 4. Phase I Clinical Study Report 5. Phase III Clinical Study Report 6. Clinical Overview (CTD 2.5) 7. Marketing Authorisation Application 8. PBRER (post-approval periodic safety report)
Orientation drill
A Phase III trial has just completed. List all the documents a medical writer would need to produce or update in the next six months.
Model list: The Clinical Study Report (CSR) for the completed Phase III trial; an update to the Investigator's Brochure reflecting the new efficacy and safety data; a Clinical Overview and Clinical Summary (CTD Module 2) if this trial supports an upcoming submission; the next scheduled DSUR if other trials in the programme are still ongoing; and possibly an update to the Risk Management Plan if new safety signals were observed.
Orientation drill
Your company is planning an NDA submission. The regulatory affairs team asks which clinical documents are "writer-owned." List them.
Model answer: Medical writers typically own the Clinical Study Reports (Module 5), the Clinical Overview (2.5), the Clinical Summary (2.7, including its subsections), patient narratives, and the Investigator's Brochure. Quality/CMC content (Module 3) and nonclinical study reports (Module 4) are typically owned by other functions, though writers may support their integration into the overall dossier.
Reflection
Think of a document you have heard mentioned at work. Where does it fall on this development timeline?
If you cannot place it yet, that is useful information — note it as a term to look up.
Module 1.2 complete
The Common Technical Document (CTD/eCTD)
Week 1 · Module 3
The Common Technical Document (CTD/eCTD)
Learning the five-module structure that organises every major regulatory submission
25 min3 quizzes2 drills
Your scenario
A senior medical writer asks a new hire to "check the Module 2.7.3 table." The new hire has no idea what this refers to. Understanding that this means the Summary of Clinical Efficacy — and being able to picture where that sits within the larger submission — is essential to functioning on a regulatory writing team.
The five CTD modules
The Common Technical Document (CTD) is the internationally agreed structure for organising a marketing application. It has five modules:
Module 1: Administrative and regional information — this module is not harmonised and differs by region
Module 2: Summaries — the synthesis layer of the whole submission
Module 3: Quality (Chemistry, Manufacturing, and Controls / CMC)
Module 4: Nonclinical study reports
Module 5: Clinical study reports
Module 2 in detail
Module 2 is where medical writers spend the most time, because it is the narrative summary layer sitting above the raw data:
2.4 Nonclinical Overview
2.5 Clinical Overview
2.6 Nonclinical Summary
2.7 Clinical Summary, with subsections:
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
2.7.2 Summary of Clinical Pharmacology Studies
2.7.3 Summary of Clinical Efficacy
2.7.4 Summary of Clinical Safety
2.7.5 References
2.7.6 Synopses of Individual Studies
Worth memorising
Picture the CTD as a triangle — Module 1 at the top, Modules 3 through 5 forming the wide base of raw data (quality, nonclinical, clinical), and Module 2 as the layer in between that synthesises everything below it into a readable narrative. Summaries in Module 2 draw directly on the underlying data in Modules 3–5; they do not stand alone.
eCTD — the electronic format
eCTD (electronic Common Technical Document) is the standardised electronic format used to assemble and submit the CTD to regulatory authorities. It is not a different set of content — it is the technical packaging (XML backbone, folder structure, and lifecycle metadata) that lets authorities track submissions and their amendments over time. Nearly all major submissions today are filed electronically in eCTD format.
What a medical writer typically owns
Writers most commonly author or coordinate Module 2 summaries (2.4, 2.5, 2.6, 2.7 and its subsections) and the individual Clinical Study Reports in Module 5. Module 3 (Quality/CMC) is typically owned by CMC or regulatory chemistry teams, and Module 4 (nonclinical reports) by toxicologists and nonclinical scientists, though writers may still be asked to support their integration or formatting.
ICH CTD Authoring Allocation: Medical Writer Responsibilities Across Module 2 & Module 5
CTD Section
Document Title
Typical Page Length
Primary Source Data
Medical Writer Focus & Governance
Module 2.5
Clinical Overview
30–80 pages
Integrated Efficacy & Safety across all trials (Module 2.7, Module 5)
Critical scientific analysis of benefit-risk balance, target product profile, justification of dosing and trial endpoints. Written by senior regulatory writers and clinical leads.
Module 2.7.1
Summary of Biopharmaceutics & Analytical Methods
20–50 pages
In vitro dissolution, bioequivalence, and bioanalytical validation reports
Bioequivalence comparisons between clinical trial formulations and commercial formulations.
Module 2.7.2
Summary of Clinical Pharmacology Studies
40–120 pages
Phase I PK/PD, food effect, DDI, and organ impairment studies
All Phase II/III CSRs (Module 5), ISE (Integrated Summary of Efficacy)
Cross-study pooling, demographic subgroups, consistency of primary/secondary endpoints across global patient populations.
Module 2.7.4
Summary of Clinical Safety
100–400 pages
All Phase I–III CSRs, ISS (Integrated Summary of Safety)
Total drug exposure (patient-years), adverse events of special interest (AESIs), common TEAEs, laboratory shifts, and deaths.
Module 5
Clinical Study Reports (CSRs)
150–500+ pages (plus Appendices)
Individual study Protocol, SAP, and TFL Output Pack
Standalone ICH E3-compliant clinical study reports for each completed trial. Core entry deliverable for regulatory medical writers.
Knowledge check
Module 2.5 of the CTD contains:
A Nonclinical Overview
B Summary of Clinical Efficacy
C Clinical Overview
D Individual clinical study reports
Knowledge check
Which CTD module contains the actual individual clinical study reports?
A Module 2
B Module 3
C Module 4
D Module 5
Knowledge check
What is eCTD?
A The standardised electronic format for regulatory submissions
B A separate set of content requirements used only for biologics
C A published scientific assessment report issued after approval
D A safety reporting template used only post-approval
Orientation drill
Match each CTD module number to its content description.
Module numbers: 2.5, 2.7.3, 2.7.4, 3.2.P, 4.2, 5.3.5.1
Descriptions:
A. Clinical Overview
B. Summary of Clinical Efficacy
C. Summary of Clinical Safety
D. Drug Product information (Quality/CMC)
E. Nonclinical study reports
F. Reports of post-marketing experience
2.5 → A (Clinical Overview) 2.7.3 → B (Summary of Clinical Efficacy) 2.7.4 → C (Summary of Clinical Safety) 3.2.P → D (Drug Product information) 4.2 → E (Nonclinical study reports) 5.3.5.1 → F (Reports of post-marketing experience)
Orientation drill
A regulatory lead tells you: "We need the clinical efficacy narrative and the safety summary updated." Identify the exact CTD sections they are referring to.
Model answer: "Clinical efficacy narrative" refers to Module 2.7.3 (Summary of Clinical Efficacy). "Safety summary" refers to Module 2.7.4 (Summary of Clinical Safety). Both are subsections of the Clinical Summary (2.7) within Module 2.
Reflection
Without looking back at this module, can you name what lives in Module 2, Module 4, and Module 5? Check your answer against the module above.
If you struggled, revisit the triangle image — Module 1 at the top, Modules 3–5 as the data base, Module 2 as the summary layer.
Module 1.3 complete
ICH guidelines beyond GCP
Week 1 · Module 4
ICH Guidelines Beyond GCP
A reading-level map of the ICH guidelines a medical writer will need to look up
20 min3 quizzes2 drills
Your scenario
A writer preparing a Clinical Study Report is told to "follow E3 structure." They need to recognise that ICH E3 is the guideline defining the structure and content of a CSR — and to know, in general terms, what the rest of the ICH "E" (Efficacy) series covers, so they know which document to open for which task.
The key ICH guidelines a writer encounters
ICH E3 — Structure and Content of Clinical Study Reports. This is the medical writer's single most important reference for CSR authoring — it defines section numbering, required content, and appendix structure.
ICH E6 (GCP) — Good Clinical Practice. Covered in depth in the dedicated ICH-GCP course; here it is enough to recognise it as the foundational quality standard for how clinical trials are designed, conducted, recorded, and reported.
ICH E8 — General Considerations for Clinical Studies. A high-level guide to overall study design and quality-by-design thinking in trial planning.
ICH E9 — Statistical Principles for Clinical Trials. The baseline reference for how a Statistical Analysis Plan should be structured and reasoned.
ICH E9(R1) — Addendum introducing the estimands framework, a newer and increasingly central way of precisely defining what a clinical trial is actually trying to estimate.
ICH E17 — Multiregional Clinical Trials. Guidance on planning and interpreting trials conducted across multiple regions simultaneously.
ICH M4E — Guidance specific to CTD Module 2 efficacy content (the Clinical Overview and Clinical Summary).
ICH E2E — Pharmacovigilance Planning. Guidance on developing a Pharmacovigilance Plan as part of risk management.
The real skill
You will never memorise all ICH guidelines — there are dozens across efficacy, safety, quality, and multidisciplinary topics. The skill this module builds is knowing which one to open when you get an assignment: told to write a CSR, you reach for E3; told to review a SAP, you reach for E9; told to address a multiregional trial's summary, you reach for E17 and M4E together.
Knowledge check
Which ICH guideline defines the structure of a Clinical Study Report?
A E6
B E3
C E9
D E17
Knowledge check
ICH E9(R1) introduced which framework for defining clinical trial objectives?
A Risk-based monitoring
B Adaptive design
C Estimands
D Multiregional trial planning
Knowledge check
Which ICH guideline(s) would you consult when writing a clinical summary for a multiregional trial?
A E6 only
B E2E only
C E8 only
D E17 and M4E
Orientation drill
For each writing task below, identify which ICH guideline is the primary reference.
1. Structuring a Clinical Study Report
2. Writing a Statistical Analysis Plan section on estimands
3. Assessing whether a trial design meets general quality standards
4. Preparing a Pharmacovigilance Plan
5. Writing the Clinical Summary for a trial run across 12 countries
1. ICH E3 2. ICH E9(R1) 3. ICH E8 4. ICH E2E 5. ICH E17 (and M4E for the Module 2 writing format)
Orientation drill
You are assigned your first CSR. List the ICH guidelines you would download before starting, and for each, what specific section you would need.
Model list:ICH E3 — the full structure and content guideline, to confirm section numbering and required content for each part of the report. ICH E6 (GCP) — to confirm the trial was conducted to the expected quality and ethical standard, which the CSR must reflect. ICH E9 — the statistical principles section relevant to the analysis population and methods actually used in this trial. ICH E9(R1) — if the SAP defined an estimand, to ensure the CSR's efficacy narrative is consistent with that framework. ICH M4E — if this CSR will feed into a CTD Module 2 summary, to align terminology and structure in advance.
Reflection
Which ICH guideline discussed in this module do you expect to reach for most often in your intended career path?
There is no wrong answer here — the goal is to build the habit of anticipating which guideline an assignment calls for.
Module 1.4 complete
Pharmacovigilance and safety landscape
Week 2 · Module 1
Pharmacovigilance and Safety Landscape
The vocabulary of drug safety — what these documents are, not how to write them
20 min2 quizzes2 drills
Your scenario
A writer receives an assignment to "support the PBRER" and has no idea what this involves or who it goes to. They need to recognise, at minimum, what a PBRER is, what feeds into it, and where it fits in the broader pharmacovigilance system — without yet needing to know how to draft one.
The pharmacovigilance framework
GVP (Good Pharmacovigilance Practices) is the EMA's set of modular guidelines governing how pharmacovigilance activities should be conducted across the EU. It is organised into numbered modules, each covering a specific pharmacovigilance process (e.g., signal management, risk management planning, periodic safety reporting).
Key safety documents and terms
ICSR (Individual Case Safety Report): The fundamental building block of pharmacovigilance — a report describing a single patient's suspected adverse reaction to a medicine. Every other safety document is ultimately built from aggregated ICSRs.
PSUR / PBRER (Periodic Benefit-Risk Evaluation Report): A regular, comprehensive review of a marketed product's benefit-risk profile, based on accumulated safety data since the previous report.
DSUR (Development Safety Update Report): The equivalent periodic safety report for products still in clinical development (investigational products), rather than marketed ones.
RMP (Risk Management Plan): A document describing a product's known and potential risks and the measures in place to characterise, prevent, or minimise them.
MedDRA: The standardised medical terminology used to code adverse events consistently, organised into Preferred Terms and grouped into System Organ Classes, so that similar events can be counted and compared across cases.
Vocabulary check
"PBRER" replaced "PSUR" as the formal EU regulatory term, but "PSUR" is still used informally and remains the term used in ICH E2C(R2). In practice, the two terms refer to the same type of periodic safety report — do not treat them as two different documents.
This module gives you the vocabulary of pharmacovigilance so you can recognise these terms when they appear in emails, meetings, and source documents. The dedicated PV/Safety Writing domain course teaches you how to actually author ICSR narratives, PBRERs, and RMPs.
Knowledge check
What is the fundamental building block of pharmacovigilance data?
A The Individual Case Safety Report (ICSR)
B The PBRER
C The Risk Management Plan (RMP)
D MedDRA
Knowledge check
Which safety document is required for investigational products during clinical development?
A PBRER
B DSUR — Development Safety Update Report
C EPAR
D Complete Response Letter
Orientation drill
Match each safety abbreviation to its full name and one-line purpose.
Abbreviations: ICSR, PBRER, DSUR, RMP, SUSAR
ICSR — Individual Case Safety Report — a single report of a suspected adverse reaction in one patient. PBRER — Periodic Benefit-Risk Evaluation Report — a regular, comprehensive review of a marketed product's benefit-risk profile. DSUR — Development Safety Update Report — the periodic safety report for products in clinical development. RMP — Risk Management Plan — describes known/potential risks and the measures used to manage them. SUSAR — Suspected Unexpected Serious Adverse Reaction — an individual serious adverse event that is both unexpected and suspected to be related to the investigational product, requiring expedited reporting.
Orientation drill
A colleague says: "The signal in the latest PSUR needs to go into the RMP update." Explain what this sentence means in plain language (150 words max).
Model explanation: A "signal" is a new or emerging piece of safety information suggesting a possible causal link between a medicine and an adverse event, which was identified while preparing the most recent periodic safety report (PSUR/PBRER). Because this is new safety information, it needs to be reflected in the product's Risk Management Plan — the document that lists known and potential risks and how they are being monitored or minimised. In practice, this means the safety team needs to add or update a risk in the RMP, and possibly propose new risk-minimisation measures, based on what was found while compiling the periodic report.
Reflection
Which of these safety terms was least familiar to you before this module? Write a one-sentence definition in your own words.
Writing your own definition — rather than recalling the module's wording — tests whether the term has really landed.
Module 2.1 complete
Medical devices: a different regulatory world
Week 2 · Module 2
Medical Devices: A Different Regulatory World
Why device regulation uses a different vocabulary and evidence model than drugs
20 min2 quizzes2 drills
Your scenario
A writer trained in pharmaceutical regulatory work is given a medical device CER assignment and is confused — there is no Phase III trial, no NDA, and the regulatory framework uses completely different terms. They need to understand that devices are regulated through a fundamentally different logic before they can make sense of the assignment.
Why devices are regulated differently
Drug regulation is built around dose-response pharmacology and controlled clinical trials. Device regulation is built around risk classification and, in many cases, comparison to devices already known to be safe and effective:
Class-based risk: Devices are classified by risk level (low to high), and the evidence required scales with that risk class.
Predicate devices: Many device pathways allow a new device to be cleared by demonstrating it is substantially equivalent to an already-marketed "predicate" device, rather than proving efficacy from scratch.
Clinical evaluation vs. clinical trials: Devices are frequently assessed through a broader "clinical evaluation" that can include literature review and registry data, not only new clinical trials.
EU MDR
The EU Medical Device Regulation (MDR, 2017/745) is the framework governing devices sold in the EU. Under MDR, most devices require CE marking, and higher-risk devices require assessment by a Notified Body — an independent organisation designated to assess conformity with the regulation. The core clinical evidence route under MDR is the clinical evaluation, documented in a Clinical Evaluation Report.
FDA device pathways
510(k): A premarket notification demonstrating that a device is "substantially equivalent" to an already legally marketed predicate device — the most common pathway for low-to-moderate risk devices.
PMA (Pre-Market Approval): The most rigorous FDA device pathway, required for high-risk (Class III) devices, generally requiring clinical trial data demonstrating safety and effectiveness.
De Novo: A pathway for novel, low-to-moderate risk devices that have no valid predicate to compare against.
Clinical Evaluation Reports (CERs)
A Clinical Evaluation Report is the core clinical document in the EU device pathway. It compiles and appraises clinical data — which may come from the manufacturer's own clinical investigations, but very often comes primarily from a systematic literature review of published data on the device or equivalent devices, along with post-market surveillance data. This is the single biggest conceptual shift for a writer moving from drugs to devices.
The biggest adjustment for pharma-trained writers
In devices, the Clinical Evaluation Report replaces the Clinical Study Report as the central clinical document. It draws on literature and registry data, not only on the manufacturer's own clinical investigations — a very different evidentiary model from a pivotal Phase III trial.
Knowledge check
What is a 510(k) submission?
A A rigorous approval pathway requiring full clinical trial data for high-risk devices
B A pathway used only when no predicate device exists
C A premarket notification demonstrating substantial equivalence to a legally marketed predicate device
D A periodic post-marketing safety report for devices
Knowledge check
Under EU MDR, who performs the conformity assessment for Class III (high-risk) devices?
A The EMA
B The device manufacturer, through self-certification
C The FDA
D A Notified Body
Orientation drill
Fill in a comparison table: Drug regulatory pathway vs Device regulatory pathway, across these rows: terminology, key documents, approval body, evidence requirements.
Terminology: Drugs — NDA/MAA, approval. Devices — 510(k)/PMA/De Novo (US), CE marking (EU).
Approval body: Drugs — FDA (CDER/CBER), EMA (CHMP). Devices — FDA (CDRH), EU Notified Bodies under MDR.
Evidence requirements: Drugs — dedicated clinical trials, typically Phase I–III. Devices — often literature review plus registry/post-market data, with new clinical investigations required mainly for higher-risk or novel devices.
Orientation drill
Explain to a pharma-trained colleague why a medical device company might submit a CER based entirely on published literature, without conducting their own clinical trial.
Model explanation: Under EU MDR, a Clinical Evaluation Report does not have to be based on the manufacturer's own clinical investigation if there is sufficient published clinical data on the device itself, or on an equivalent device, to demonstrate conformity with the relevant safety and performance requirements. If the device is well established — for example, a type of surgical mesh or a class of orthopaedic implant with years of published outcome data — running a new clinical trial would be unnecessary duplication. The manufacturer instead conducts a systematic literature review, appraises the quality and relevance of the identified studies, and combines this with their own post-market surveillance data to build the clinical evaluation. This is fundamentally different from drug development, where a novel compound has no pre-existing published safety and efficacy data to draw on.
Reflection
What is the single biggest mental adjustment a pharma-trained writer must make when moving into device regulatory writing?
Consider the shift from trial-based evidence to literature-and-registry-based evidence.
Module 2.2 complete
Regional variations & expedited approval pathways
Week 2 · Module 3
Regional Variations: US, EU, Japan, India
Understanding why the same product looks different in different regulatory dossiers
25 min3 quizzes2 drills
Your scenario
A writer working on a global dossier is told that "the Japan module needs different formatting and the India submission requires additional local data." They need to understand why regions differ — not just accept it as an inconvenience — so they can anticipate these differences on future projects.
Why review processes differ
The FDA and EMA differ in review structure: the FDA conducts its own internal review with defined timelines and may convene an advisory committee of external experts for complex cases, while the EMA's review is coordinated through a rapporteur system, where one or two member states lead the scientific assessment on behalf of the CHMP before the committee issues its opinion.
Japan (PMDA) has a distinctive requirement rooted in ICH E5 (ethnic factors in the acceptability of foreign clinical data): because ethnic differences can affect drug response, sponsors are often required to demonstrate that foreign clinical data are applicable to the Japanese population, sometimes through a dedicated bridging study.
India (CDSCO) has historically required local clinical trial data for many products before approval, reflecting concerns about applicability of foreign data to the Indian population, though recent regulatory reforms have streamlined some requirements, particularly for products already approved in reference markets.
Accelerated and special pathways
FDA: Breakthrough Therapy designation (intensive guidance and rolling review for serious conditions), Fast Track, Priority Review, and Accelerated Approval (based on surrogate endpoints, with confirmatory trials required post-approval).
EMA: PRIME (PRIority MEdicines, enhanced support for promising therapies), Conditional Marketing Authorisation, and Accelerated Assessment.
Pediatric requirements: The FDA's PREA (Pediatric Research Equity Act) and the EU's Pediatric Regulation (EC No 1901/2006), which requires a Pediatric Investigation Plan (PIP) describing how a product will be studied in children.
Orphan drug designations: Both the FDA and EMA offer designations for products treating rare diseases, providing incentives such as extended market exclusivity and reduced fees.
Generic/biosimilar pathways: The FDA's ANDA (Abbreviated New Drug Application) for generics, and the EMA's dedicated biosimilar pathway, which requires a comparability exercise against the reference biologic rather than a full independent development programme.
Master Comparison Matrix: Expedited & Special Regulatory Pathways (FDA vs EMA vs PMDA vs CDSCO)
Regulators provide specialized pathways to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need:
Agency / Jurisdiction
Pathway / Designation
Eligibility Criteria
Key Regulatory Benefits
Post-Approval Commitments
US FDA
Fast Track
Treats serious condition AND demonstrates potential to address unmet medical need.
Frequent FDA interactions, rolling review of completed BLA/NDA modules.
Standard post-marketing requirements (PMRs).
Breakthrough Therapy
Treats serious condition AND preliminary clinical evidence indicates substantial improvement over available therapy on ≥1 clinically significant endpoint.
All Fast Track features + intensive FDA senior management guidance and organizational commitment.
Expedited clinical development timeline; possible smaller trials.
Accelerated Approval (Subpart H / Subpart E)
Treats serious condition, provides meaningful advantage over available therapies, and demonstrates effect on a surrogate endpoint reasonably likely to predict clinical benefit.
Early market access based on surrogate or intermediate clinical endpoints (e.g., tumor response rate, biomarker clearance).
Mandatory Phase IV confirmatory trials to verify clinical benefit. Approval may be withdrawn if confirmatory trial fails.
Priority Review
Significant improvement in safety or efficacy in treatment, diagnosis, or prevention of a serious condition.
Shortened NDA/BLA review clock from standard 10 months to 6 months.
Standard post-marketing obligations.
EMA (European Union)
PRIME (Priority Medicines)
Major public health interest and potential to address unmet medical need with early clinical data showing promise.
Dedicated CHMP rapporteur assignment, early multi-stakeholder scientific advice, iterative development feedback.
Standard MAA submission with optimized dossier.
Conditional Marketing Authorisation (CMA)
Positive benefit-risk balance, unmet medical need, benefit of immediate availability outweighs risk of less comprehensive data.
One-year renewable European authorization granted before complete Phase III data are available.
Specific post-authorization obligations (SOBs) to complete ongoing or new confirmatory trials within defined timelines.
Accelerated Assessment
Product of major interest from the point of view of public health and therapeutic innovation.
Reduces CHMP evaluation timeline from standard 210 days to 150 days.
Standard marketing authorization requirements.
PMDA (Japan)
Sakigake Designation
World-first development initiated in Japan for life-threatening diseases with prominent effectiveness.
Priority consultation (shortened to 1 month), pre-filing review, target review period reduced to 6 months.
Post-marketing all-case surveillance and rigorous PMS registries.
CDSCO (India)
Accelerated Approval / Special Pathway (NDCT 2019 Rule 101)
New drugs for rare diseases, life-threatening diseases, or public health emergencies.
Waiver of local clinical trials, fast-track SEC review, approval based on global Phase II/III data with surrogate markers.
Phase IV post-marketing study required within defined timeline unless specifically waived by DCGI.
Knowledge check
What is a "bridging study" in the context of Japanese regulatory submissions?
A A study conducted to determine if foreign clinical data are applicable to the Japanese population
B A post-marketing study conducted after approval to monitor long-term safety
C A study comparing a new device to a predicate device
D A study required to extend a product\'s use into a pediatric population
Knowledge check
Which FDA designation provides intensive guidance and rolling review for serious conditions?
A Fast Track designation
B Breakthrough Therapy designation
C Orphan drug designation
D PREA
Knowledge check
Under which regulation must sponsors submit a Pediatric Investigation Plan in the EU?
A PREA
B EU MDR
C Pediatric Regulation (EC No 1901/2006)
D ICH E5
Orientation drill
Your company has a drug approved in the US and EU. List three key differences they would need to address for a PMDA submission in Japan.
1. Ethnic sensitivity assessment: Under ICH E5, the sponsor must assess whether pharmacokinetic and efficacy/safety data from the Western population can be extrapolated to Japanese patients, potentially requiring a bridging study.
2. Pre-submission consultation: Rather than filing directly, the sponsor typically engages in PMDA's structured consultation process to align on the data package before formal submission.
3. Format and administrative differences: Module 1 (administrative/regional information) content and formatting requirements differ for Japan, and some local documentation and Japanese-language materials are required even though Modules 2–5 remain broadly harmonised.
Orientation drill
Given the scenario of an orphan drug for a rare lysosomal storage disorder, identify the applicable regulatory pathway and incentives in both the US and EU.
US: The sponsor would seek FDA Orphan Drug Designation, which provides incentives including tax credits for clinical testing, waiver of certain user fees, and seven years of market exclusivity upon approval. Given the rarity and severity of a lysosomal storage disorder, the sponsor might also qualify for Breakthrough Therapy or Fast Track designation if early data show meaningful benefit, and may rely on a single-arm trial design given feasibility constraints.
EU: The sponsor would seek EMA Orphan Medicinal Product designation, which provides ten years of market exclusivity, protocol assistance (scientific advice), and reduced fees. The product may also be eligible for PRIME designation given the seriousness and unmet need, and the EMA's guideline on clinical trials in small populations would support a non-traditional evidence package.
Reflection
If you worked on a global submission, which regional difference discussed here do you think would surprise you most in practice?
Consider format, timelines, local data requirements, or the accelerated pathway landscape.
Module 2.3 complete
Regulatory agency meetings & briefing packages
Week 2 · Module 4
Regulatory Agency Meetings & Briefing Packages
Authoring Type A, B, and C meeting briefing documents for the FDA and Scientific Advice packages for the EMA
28 minBriefing booksType B meetingsEMA Scientific Advice3 drills
Your scenario
Your clinical team is preparing for an End-of-Phase 2 (EOP2) Type B Meeting with the FDA Division of Cardiology. The project lead asks you to draft the Background Briefing Package. If your briefing document frames the questions vaguely (e.g. “Does the Agency agree our Phase III trial is adequate?”), the FDA will issue unhelpful, non-committal preliminary responses. A senior regulatory medical writer knows how to draft precise, defensible Sponsor Position Statements that force clear regulatory alignment on Phase III primary endpoints, sample size assumptions, and pediatric deferrals.
The Structure of FDA Formal Meetings (PDUFA VI / VII)
Interactions between pharmaceutical sponsors and health authorities are formal, legally structured negotiations governed by strict statutory timelines. Under FDA PDUFA guidelines, formal meetings are classified into three core tiers:
Type A Meetings (Urgent / Clinical Holds): Necessary for an otherwise stalled product development program to proceed (e.g. dispute resolution, discussing clinical holds, special protocol assessment [SPA] disagreements). Scheduled within 30 days of request.
Type B Meetings (Critical Milestones): Standard milestone consultations: Pre-IND (prior to first-in-human), End-of-Phase 1 (EOP1), End-of-Phase 2 (EOP2 / Pre-Phase 3), and Pre-NDA / Pre-BLA meetings. Scheduled within 60 days of request.
Type C Meetings (General Guidance): Any other meeting regarding the development and review of a product (e.g. biomarker assay validation, secondary endpoint hierarchy discussion). Scheduled within 75 days of request.
Anatomy of an Audit-Ready Briefing Book: The Sponsor Question & Position Strategy
A Briefing Document is not an exploratory discussion paper; it is a persuasive, data-driven justification of the sponsor’s planned development program. Every issue in a briefing book follows a strict 3-part anatomy:
Briefing Component
Content & Structure
Writing Guardrail
1. Specific Question
A focused, binary question addressing one specific regulatory, clinical, or statistical issue.
Always phrase as:“Does the Agency agree that [specific proposal] is acceptable to support [specific regulatory objective]?” Never ask open-ended questions like “What should we do?”
2. Sponsor's Position
A concise (1–2 paragraph) executive summary of the sponsor's proposal, stating the exact clinical or methodological rationale.
State the proposed design parameters explicitly (e.g., “The sponsor proposes a 1:1 randomised, double-blind design with a primary composite endpoint of 3-point MACE...”).
3. Supporting Background & Data
Comprehensive synthesis of Phase I/II PK/PD, safety, dose-finding results, and statistical modeling that justifies the position.
Cross-reference Phase II CSR tables and include literature precedent / FDA guidance citations.
Knowledge check
Why must every question in an FDA Briefing Document be followed immediately by a detailed Sponsor Position Statement?
A It is required only for oncology accelerated approvals
B It replaces the need for a face-to-face meeting
C It is only required if the meeting is classified as Type A
D Regulators do not design clinical trials for sponsors; they review and critique the sponsor\'s specific scientific rationale and proposed plan
Production drill
Convert the following poorly phrased team question into a professional, audit-ready Briefing Package Question and Sponsor Position for an End-of-Phase 2 meeting: Poor phrasing: "We want to know what the FDA thinks about our proposed 12-week Phase III primary endpoint in severe plaque psoriasis."
Model Briefing Document Section:
Question 3 (Clinical Efficacy): “Does the Agency agree that co-primary efficacy endpoints of the proportion of subjects achieving PASI-90 and the proportion achieving static Physician Global Assessment (sPGA) 0/1 (clear or almost clear with ≥2 grade improvement) at Week 12 are acceptable to support a Biologics License Application (BLA) for the treatment of moderate-to-severe plaque psoriasis?”
Sponsor Position:
The sponsor proposes co-primary endpoints of PASI-90 and sPGA 0/1 at Week 12. In the completed Phase II dose-ranging trial (Study 201, Section 5.2 of this briefing package), the 150 mg dose demonstrated rapid onset of efficacy, with 74.2% of subjects achieving PASI-90 at Week 12 compared to 11.4% on placebo (p < 0.001), with plateau of maximal response maintained through Week 24. Furthermore, Week 12 co-primary assessment aligns with FDA Guidance for Industry: Psoriasis — Developing Drugs for Treatment and ICH E10 active-comparator trial standards.
Module 2.4 complete
Pediatric regulations & global pediatric plans (PIP/iPSP)
Week 3 · Module 1
Pediatric Regulations & Global Pediatric Plans (PIP / PSP)
Navigating the EU Pediatric Regulation and US PREA / BPCA — drafting Paediatric Investigation Plans, waivers, and deferrals
28 minEU PIPUS iPSPPREA / BPCA3 drills
Your scenario
Your company is developing a novel targeted therapy for adult chronic kidney disease and is preparing its adult Phase III program. Two months before filing the adult Marketing Authorisation Application (MAA) in Europe, the regulatory lead discovers the company never submitted a Paediatric Investigation Plan (PIP) to the EMA's Paediatric Committee (PDCO). In Europe, an adult MAA submission will be refused validation at day zero without an approved PIP or an official waiver letter. A regulatory medical writer must know how pediatric planning integrates into the earliest phases of adult clinical development.
Global Pediatric Mandates: EU vs US Frameworks
Historically, children were “therapeutic orphans” because drugs were approved in adults and used off-label in children without dosing or safety data. To resolve this, major regulatory agencies established statutory mandates requiring pediatric development:
European Union (EC No 1901/2006): The EU Pediatric Regulation requires sponsors to submit a Paediatric Investigation Plan (PIP) to the EMA no later than the completion of human adult pharmacokinetic studies (End of Phase 1). An approved PIP decision is a legal prerequisite for MAA validation.
United States (PREA & BPCA):
PREA (Pediatric Research Equity Act): Mandatory requirement to submit pediatric assessments for the same indication, dosage form, and dosing regimen in adults, submitted as an initial Pediatric Study Plan (iPSP) within 60 days of the EOP2 meeting.
BPCA (Best Pharmaceuticals for Children Act): Voluntary incentive program where the FDA issues a Written Request (WR) for pediatric studies, granting 6 months of additional patent and market exclusivity upon successful completion.
Complete exemption from conducting any pediatric studies across all age subsets (birth to <18 years).
The disease occurs exclusively in adults (e.g. Alzheimer's disease, senile osteoporosis, prostate cancer); or the drug is likely to be ineffective or unsafe in children.
Class Waiver (EU)
Specific drug classes or conditions exempted on the EMA official class waiver list.
Conditions that do not occur in pediatric populations (e.g., chronic lymphocytic leukemia).
Partial Waiver
Waiver for specific age subsets (e.g. neonates 0–27 days or infants <2 years).
Clinical condition does not exist in neonates, or adult oral formulation cannot safely be adapted to infants.
Deferral
Permission to postpone pediatric studies until adult efficacy and safety data are established.
Standard strategy: allows adult MAA/NDA approval to proceed while pediatric Phase II/III trials are conducted post-approval under binding completion timelines.
Knowledge check
In the European Union, at what development milestone must a sponsor submit a Paediatric Investigation Plan (PIP) to the EMA Paediatric Committee (PDCO)?
A No later than the completion of human adult pharmacokinetic studies (End of Phase 1)
B Simultaneously with the adult MAA marketing submission
C Only after adult Phase III clinical trials are completed and unblinded
D Prior to filing the first-in-human IND application
Production drill
A sponsor is developing a novel GLP-1/GIP dual agonist for adult Type 2 Diabetes. Outline the global pediatric strategy: Would you apply for a full waiver, partial waiver, or deferral? Specify the age subsets (neonates, children, adolescents) and justify your regulatory rationale for the EU PIP and US iPSP.
Global Pediatric Strategy: Type 2 Diabetes GLP-1/GIP Agonist
1. Age Subset Allocation:
- Birth to <10 years (Neonates, Infants, Young Children): Request a Partial Waiver on grounds that Type 2 Diabetes occurs exceptionally rarely in children under 10 years of age, and the clinical condition is primarily driven by Type 1 Diabetes in this age cohort.
- 10 to <18 years (Adolescents & Older Children): Propose a dedicated pediatric development program (Phase II PK/PD dose-finding followed by double-blind Phase III efficacy/safety against metformin standard of care).
2. Regulatory Mechanism (Deferral):
- Request a Deferral in both the EU PIP and US iPSP to initiate the adolescent Phase III trial only after safety and efficacy are formally established in adult Phase III (to avoid exposing pediatric subjects to uncharacterized risks).
- Propose developing an age-appropriate autoinjector device or lower-concentration liquid formulation tailored for pediatric body weights.
Module 3.1 complete
505(b)(2) hybrid submissions & biosimilar totality of evidence
A specialty pharmaceutical client wants to develop a novel sublingual fast-dissolving formulation of an approved oral tablet for acute breakthrough pain. The project manager asks whether you need to author a standard 100-page Module 2.7.3 Clinical Efficacy Summary with large Phase III trials. As a regulatory medical writer, you recognize this qualifies for an FDA 505(b)(2) NDA (or an EU Article 10(3) Hybrid Application). By designing a scientifically sound PK bridging study that demonstrates bioequivalence and safety, the sponsor can rely on the FDA's prior findings of efficacy for the reference listed drug, saving $40M and 3 years of clinical trial development.
The Three Regulatory Pathways for Small Molecules (US FDA)
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), small-molecule pharmaceutical applications follow three distinct legal routes:
505(b)(1) Standalone NDA: Full development dossier. All preclinical and clinical investigations were conducted by or for the sponsor, and the sponsor has full right of reference to all raw data.
505(j) ANDA (Abbreviated New Drug Application): True generic drugs. The sponsor demonstrates identical active ingredient, dosage form, strength, route, and bioequivalence (90% CI of geometric mean ratios for AUC and Cmax between 80.00% and 125.00%) to the Reference Listed Drug (RLD). No preclinical toxicology or Phase III clinical efficacy trials required.
505(b)(2) Hybrid NDA: Contains full reports of safety and efficacy, but at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference (relying on FDA’s published findings of safety/efficacy for an approved RLD or published peer-reviewed literature).
Biologics vs Biosimilars: The Totality-of-the-Evidence Model
Because biological products (monoclonal antibodies, recombinant proteins) are large, complex molecules manufactured in living cell lines, exact generic copies cannot be made. Instead, regulators evaluate Biosimilars (FDA 351(k) / EMA Biosimilar MAA) using a reverse evidence pyramid:
Authored in Module 4 (Nonclinical) and summarized in Module 2.4/2.6.
3. Clinical PK / PD Equivalence
Phase I comparative PK (AUC, Cmax) and PD biomarkers in healthy volunteers or sensitive patient populations.
Authored in Module 5 (Study Reports) and summarized in Module 2.7.1 / 2.7.2.
4. Confirmatory Clinical Trial & Immunogenicity
One sensitive, randomized clinical trial to rule out clinically meaningful differences in efficacy, safety, and anti-drug antibody (ADA) immunogenicity.
Authored in Module 2.7.3/2.7.4 and Module 2.5 Clinical Overview, supporting Extrapolation of Indications across all approved adult indications of the reference biologic.
Knowledge check
What is the primary scientific mechanism that allows a 505(b)(2) NDA applicant to avoid repeating multi-thousand-patient Phase III efficacy trials?
A An automatic waiver granted for any modified dosage form
B A pharmacokinetic bridging study that links the new formulation to the reference listed drug whose efficacy has already been established by the FDA
C A high SUCRA ranking in indirect treatment comparisons
D In vitro dissolution testing alone without any human PK studies
Production drill
A sponsor is authoring a Biosimilar Marketing Authorization Application for a proposed biosimilar to Trastuzumab in HER2-positive breast cancer. The sponsor completed an analytical comparability package, a Phase I PK equivalence study, and one Phase III confirmatory equivalence trial in early breast cancer. Can the medical writer draft Module 2.5 proposing extrapolation of indications to metastatic gastric cancer (which was not clinically tested in the biosimilar program)? State the scientific and regulatory justification.
Extrapolation Justification in Module 2.5 Clinical Overview:
Regulatory Conclusion: Yes, extrapolation of indications to metastatic gastric cancer is scientifically justified and permissible under FDA and EMA biosimilar guidelines.
Scientific Justification:
1. Identical Mechanism of Action: In both breast cancer and gastric cancer, trastuzumab exerts its clinical effect through binding the extracellular domain IV of the HER2 receptor, inhibiting downstream MAPK/PI3K proliferation and mediating Antibody-Dependent Cellular Cytotoxicity (ADCC).
2. Analytical & Bioassay Totality: The extensive Module 3 analytical characterization and in vitro bioassays demonstrated identical target binding affinity and equivalent ADCC potency between the biosimilar and reference product.
3. Sensitive Clinical Model: Early breast cancer served as a highly sensitive clinical model to detect any subtle potential differences in efficacy (pathological complete response [pCR]) and immunogenicity.
4. PK & Safety Concordance: Equivalent pharmacokinetic exposure and comparable incidence of anti-drug antibodies (ADAs) rule out any clinically meaningful differences in pharmacodynamics across indications.
Module 3.2 complete
Orphan drug designation & significant benefit justification
Week 3 · Module 3
Orphan Drugs & Rare Disease Regulatory Strategy
Authoring Orphan Drug Designation applications — medical plausibility, prevalence calculations, and establishing significant benefit
Your biotech client is developing an antisense oligonucleotide for Spinal Muscular Atrophy (SMA) Type 1. An existing approved gene therapy already exists on the market. To obtain EMA Orphan Drug Designation (ODD) and secure 10 years of EU market exclusivity, the sponsor cannot simply show that the condition is rare; they must submit a formal clinical dossier proving “Significant Benefit” over the existing authorized product. A medical writer who does not understand the difference between FDA prevalence criteria (<200,000 US patients) and EMA “Significant Benefit” requirements will see their orphan application rejected by the Committee for Orphan Medicinal Products (COMP).
Orphan Drug Designation: US vs EU Frameworks
Rare diseases affect small patient populations where standard commercial returns would not justify high R&D costs. To incentivize drug development, regulators established dedicated orphan drug legislation:
US FDA (Orphan Drug Act of 1983):
Prevalence Threshold: Affects fewer than 200,000 persons in the United States (or more than 200,000 if there is no reasonable expectation of cost recovery).
Incentives:7 years of market exclusivity upon marketing approval, 25% tax credits for clinical research expenses, exemption from FDA PDUFA user fees (saving ~$4M), and access to orphan grant funding.
European Union (Regulation EC No 141/2000):
Prevalence Threshold: Affects no more than 5 in 10,000 persons across the European Union (equating to <225,000 EU patients).
Severity & Medical Plausibility: Condition must be life-threatening or chronically debilitating, with scientific evidence establishing medical plausibility of the product.
Significant Benefit Requirement: If an authorized treatment already exists in the EU, the applicant must establish that the new drug will provide a clinically relevant advantage or major contribution to patient care.
Incentives:10 years of EU market exclusivity (extended to 12 years with pediatric PIP completion) and protocol assistance (scientific advice at reduced fees).
How Medical Writers Draft the EMA "Significant Benefit" Justification
Dimension of Significant Benefit
Clinical Definition
Medical Writer Evidence Strategy
1. Improved Efficacy
Better clinical outcomes (higher survival, superior response rates, slower disease progression) compared to existing therapy.
Cite comparative nonclinical models, early clinical biomarker suppression, or superior response rates in refractory patient subsets.
2. Improved Safety Profile
Substantial reduction in serious adverse reactions or treatment-limiting toxicities.
Document absence of severe organ toxicities (e.g. no hepatotoxicity or cardiotoxicity seen with current standard of care).
3. Major Contribution to Patient Care (MCPC)
Meaningful improvement in patient convenience, adherence, or quality of life (e.g. oral daily dosing vs painful monthly intrathecal hospital injections).
Provide pharmacokinetic stability data, patient burden surveys, and adherence modeling.
Knowledge check
Under EU orphan regulations, if an effective medicine is already authorized for a rare disease, what must the sponsor demonstrate to successfully obtain Orphan Drug Designation?
A A lower commercial acquisition cost than the existing therapy
B That the product was manufactured within the European Union
C Significant Benefit over the existing authorized treatment (improved efficacy, improved safety, or major contribution to patient care)
D Only that the prevalence is below 5 in 10,000 without comparing to existing treatments
Production drill
A biotech is drafting an EMA Orphan Drug Designation application for an oral small molecule treating adult Cystic Fibrosis with G551D mutations. An approved intravenous/inhalation standard of care exists. Draft the 150-word "Significant Benefit" executive justification for Module 2 of the orphan dossier based on oral route of administration and absence of severe pulmonary bronchospasm adverse events.
Model Significant Benefit Justification:
“The proposed investigational product represents a Significant Benefit over currently authorized therapies in the European Union for patients with Cystic Fibrosis harboring G551D mutations on two distinct grounds: improved clinical safety and a major contribution to patient care.
Firstly, in completed Phase I/II clinical trials (Study CF-102), oral administration achieved sustained therapeutic plasma concentrations without triggering acute bronchospasm, chemical pneumonitis, or severe airway hyperreactivity, which are documented treatment-limiting adverse reactions associated with current aerosolized inhalation therapies.
Secondly, the once-daily oral tablet formulation eliminates the requirement for complex, 45-minute daily nebulization regimens and specialized clinic visits, substantially reducing treatment burden, improving long-term therapeutic adherence, and offering a major contribution to patient quality of life. Together, these data establish clinical plausibility of Significant Benefit under Article 3(1)(b) of Regulation (EC) No 141/2000.”
Module 3.3 complete
The regulatory document universe
Week 3 · Module 1
The Regulatory Document Universe
Building a mental map of every document type you will encounter — who reads it, when, and how long it takes
25 min3 quizzes3 drills
Your scenario
A medical writing department head shows a new hire the document tracker for the department — 40 different document types across 6 active programs. The writer needs a mental map of how all of these documents relate to one another, or the tracker will remain an overwhelming wall of acronyms.
Four ways to organise the document universe
Rather than memorising 40 documents individually, it helps to sort them along four dimensions:
Who reads it — regulators, investigators, IRBs/Ethics Committees, or internal teams
When it is written — which development phase produces or requires it
How long it takes — quick-turnaround documents (a protocol amendment, roughly two weeks) versus extended efforts (a CSR, typically three to six months; CTD summaries, typically two to three months)
Who reviews it — the typical chain is author → medical reviewer → statistical reviewer → regulatory reviewer → quality control (QC)
Document universe explorer
Explore the document universe by audience, phase, or timeline
Documents read primarily by investigators and IRBs/Ethics Committees
Investigator's Brochure, Clinical Study Protocol, Informed Consent Forms.
Documents used primarily by internal teams
Statistical Analysis Plan, patient narratives (which feed into the CSR), internal safety updates and DSUR drafts before submission.
Extended-turnaround documents
Clinical Study Report — typically 3 to 6 months. CTD Module 2 summaries — typically 2 to 3 months. These require synthesising large datasets and passing through multiple layers of review.
Quick-turnaround documents
Protocol amendments — often around 2 weeks. Safety Update Reports for a single new signal. Minor labelling updates.
The core document list
Across your career you will repeatedly encounter: the Investigator's Brochure, the Clinical Study Protocol, the Statistical Analysis Plan, the Clinical Study Report, the Clinical Overview (2.5), the Clinical Summary (2.7), patient narratives (found in CSR Section 14.3 per ICH E3), labelling (the SmPC in the EU, the USPI in the US), safety updates (DSURs and SUSAR reports), periodic reports (PBRERs), and Informed Consent Forms.
Knowledge check
Which document type typically takes the longest to produce?
A A protocol amendment
B Informed Consent Form
C A single SUSAR report
D Clinical Study Report
Knowledge check
Patient narratives are part of which regulatory document?
A The Clinical Study Report (Section 14.3, per ICH E3)
B The Investigator\'s Brochure
C The Clinical Overview
D The Informed Consent Form
Knowledge check
Who is the primary audience for an Investigator's Brochure?
A Regulatory reviewers evaluating a marketing application
B Clinical investigators and IRBs/Ethics Committees considering the trial
C Patients enrolling in the trial
D Internal marketing teams
Orientation drill
Given the following six one-line descriptions, name the document type each refers to.
1. "Summarises the entire product safety and efficacy profile for investigators before a trial begins."
2. "Reports a single case of a suspected adverse reaction."
3. "Written primarily so a patient understands the risks and benefits of participating in a trial."
4. "Contains individual accounts of patients who died or had a serious adverse event during the trial."
5. "The high-level narrative summary of clinical efficacy submitted in CTD Module 2."
6. "A regular aggregate review of a marketed product's benefit-risk profile."
Create a timeline showing the five most critical documents a writer produces for a single Phase III trial, from protocol to submission.
1. Clinical Study Protocol — written before the trial starts, defining design, population, and endpoints. 2. Statistical Analysis Plan — finalised before database lock, defining the planned analyses. 3. Clinical Study Report — written after the trial completes and data are analysed. 4. Investigator's Brochure update — revised to reflect the new trial's safety and efficacy findings. 5. Clinical Overview / Clinical Summary (CTD Module 2) — written to integrate this trial's results into the overall submission narrative.
Orientation drill
Your manager assigns you to "support the submission team." List all the documents you might be asked to write or update for an NDA/MAA submission.
Model list: Clinical Overview (2.5), Nonclinical Overview (2.4, if supporting), Clinical Summary and its subsections (2.7.1–2.7.6), any outstanding or updated Clinical Study Reports (Module 5), the current Investigator's Brochure, the Risk Management Plan, draft labelling (SmPC/USPI), and possibly responses to anticipated regulatory questions once the submission is under review.
Reflection
Pick three documents from this module's list. For each, name who reads it and roughly how long it takes to produce.
This is the exercise you will effectively repeat every time you join a new project team.
Module 3.4 complete
Document lifecycle and quality management
Week 3 · Module 2
Document Lifecycle and Quality Management
Why formatting, versioning, and QC are regulatory risk issues — not bureaucracy
25 min3 quizzes3 drills
Your scenario
A writer submits a CSR draft with tracked changes still visible, references formatted in a different style than the company's house style, and headers copied over from a different protocol's template. Quality Control catches every one of these errors and sends the document back — costing the team a full review cycle.
The document lifecycle
A regulatory document moves through a predictable sequence: outline → first draft → internal review (medical, statistical, regulatory) → revision → QC check → finalisation → sign-off → archival in the TMF. Skipping or rushing any step is how formatting, referencing, and consistency errors reach a regulator.
Style guides and templates
Medical writing relies on established style guides — most commonly the AMA Manual of Style in the US, alongside company-specific "house styles" and, often, client-specific style guides layered on top for CRO-sponsor relationships. Template governance matters because a consistent template ensures every document of a given type has the same section numbering, headers, and required content — deviating from an approved template creates avoidable inconsistency across a submission.
Track changes and version control
Track changes etiquette is a practical skill: know what should be formally accepted before a document moves to the next reviewer, what should remain visible as an open query, and the difference between a "clean" version (accepted changes, ready for signature) and a "marked" version (all changes visible, useful for review history).
Version control and naming conventions typically follow a logic such as v0.1, v0.2 for early drafts, progressing through v0.x as a working draft, with the jump to v1.0 signalling that the document has been finalised and formally approved.
Reference management tools such as EndNote, Citavi, or Zotero are used to keep citations consistent and traceable across a long document with many source references.
SOPs and the TMF
Standard Operating Procedures (SOPs) govern how writing processes are conducted at a company — from how drafts are routed for review to how QC is performed. The Trial Master File (TMF) is the collection of essential documents that allows the conduct and management of a clinical trial to be reconstructed; a complete, correctly filed TMF is what an inspector expects to find during a regulatory inspection.
"Regulatory submission readiness" means a document is not only scientifically accurate but also correctly formatted, consistently referenced, and filed where it belongs — that combination is what "final" means in a regulated context.
Quality management is not bureaucracy
A document that is scientifically perfect but formatted incorrectly, referenced inconsistently, or filed in the wrong TMF section creates regulatory risk. Quality management is how regulated industries maintain inspection-readiness — it is a core part of the job, not an obstacle to it.
Knowledge check
What is the standard reference for medical writing style in the US?
A ICH E3
B GVP Module IX
C AMA Manual of Style
D MedDRA
Knowledge check
In version control, what does moving from v0.x to v1.0 typically indicate?
A The document has moved from final back into draft status
B A new reviewer has been assigned to the document
C The document has been moved to a different folder in the TMF
D The document has been finalised/approved — draft to final transition
Knowledge check
What is the TMF?
A Trial Master File — the collection of essential documents allowing the conduct and management of a clinical trial to be reconstructed
B A style guide used for formatting clinical documents
C A summary of a product\'s safety and efficacy given to investigators
D A periodic aggregate report of a product\'s adverse events
Orientation drill
Put the following eight document lifecycle steps in the correct order.
Steps (out of order): medical review, kickoff meeting, first draft, QC, finalisation, outline, revision, TMF filing
1. Kickoff meeting 2. Outline 3. First draft 4. Medical review 5. Revision 6. QC 7. Finalisation 8. TMF filing
Orientation drill
You receive a CSR back from QC with the following comments. Categorize each into: formatting issue, scientific content issue, or regulatory compliance issue.
1. "Table 14.2.1 uses a different font from the rest of the document."
2. "The primary endpoint definition in Section 9.1 does not match the protocol."
3. "Section 16.1.9 (list of investigators) is missing entirely."
4. "Reference 12 in the bibliography does not match the in-text citation format."
5. "The adverse event incidence in Table 12.2 does not match the numbers cited in the text."
6. "Patient narrative for Subject 0142 is missing the outcome of the SAE."
7. "Page numbers restart partway through the document."
8. "The statistical method described in Section 9.7 does not match the SAP."
9. "The signature page is missing the sponsor's authorised signatory."
10. "Heading styles are inconsistent between Section 10 and Section 11."
11. "The informed consent version referenced does not match the version used at the site."
12. "Abbreviation list is missing several terms used in the report."
13. "The CONSORT-style disposition figures do not sum correctly across arms."
14. "Section 1 (title page) protocol number does not match Section 5 (study administration)."
15. "Appendix 16.2 case report form is not the final approved version."
Formatting issues: 1, 4, 7, 10, 12
Scientific content issues: 2, 5, 6, 8, 13
Regulatory compliance issues: 3, 9, 11, 14, 15
(Some items could reasonably sit in more than one category — for example, item 2 is both a scientific and a compliance concern, since a mismatched endpoint definition could also raise questions about protocol deviation reporting. The value of this exercise is training the habit of asking which category a QC comment belongs to, not memorising a single fixed answer.)
Orientation drill
Write a brief SOP-style checklist (8-10 items) for "Final QC of a Clinical Study Report before sign-off."
Model checklist: 1. Confirm the document uses the current approved CSR template and version. 2. Confirm all tracked changes have been formally accepted or resolved, with no visible comments remaining. 3. Verify the protocol number, product name, and study number are consistent across every section, including the title page and headers. 4. Confirm the primary and secondary endpoint definitions match the protocol and SAP exactly. 5. Cross-check all in-text data references against the corresponding tables and figures. 6. Confirm the reference/bibliography formatting matches the house style guide. 7. Verify patient narratives are complete, including outcome, for every listed serious adverse event. 8. Confirm pagination, headers, and footers run consistently throughout the document. 9. Verify the signature page lists the correct, current authorised signatories. 10. Confirm the document version number reflects its true status (draft vs. final) before routing for sign-off.
Reflection
Think of a document you have submitted for review, in any context. What is one quality-control step you now realize you skipped?
Small formatting and consistency errors are often what QC catches first — and what erodes trust in a document's overall reliability.
Your commercial team wants to submit a label expansion for a targeted oncology drug to include first-line combination therapy based on a single-arm Phase II study. Before drafting the dossier, the regulatory director asks you to conduct a Regulatory Intelligence Review. You search FDA Summary Basis of Approvals (SBOA) and European Public Assessment Reports (EPAR) and discover that six months ago, the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12–1 against approving a competitor’s similar product based on single-arm data in the first-line setting. Synthesizing regulatory intelligence protects sponsors from costly clinical development dead-ends.
What is Regulatory Intelligence?
Regulatory Intelligence is the systematic process of identifying, monitoring, and analyzing publicly available regulatory information (guidance documents, advisory committee transcripts, precedent approval dossiers, and inspection findings) to guide strategic clinical authoring decisions.
Key public regulatory databases medical writers utilize:
FDA Drugs@FDA: Contains original approval packages, multidisciplinary reviews (Medical, Chemistry, Clinical Pharmacology, Statistical Reviews), Complete Response Letters, and Summary Basis of Decision (SBOD).
EMA European Public Assessment Reports (EPAR): Comprehensive scientific discussion documents detailing the CHMP's assessment of efficacy, safety, and unresolved benefit-risk questions.
FDA Advisory Committee Briefing Materials & Transcripts: Unfiltered questions, statistical debates, and voting results from independent expert panels.
Updating sponsor administrative contact details; minor specification tightening in analytical assay methods.
Major (Clinical Efficacy & Safety)
Type II Variation
Prior Approval Supplement (PAS)
Adding a new therapeutic indication; changing dosing regimen (e.g. daily to weekly); updating clinical efficacy claims based on completed Phase IV confirmatory trials.
Urgent Safety Restrictions
Type II (Urgent Safety)
Changes Being Effected in 30 Days (CBE-30) / PAS
Adding a new Boxed Warning / Contraindication; updating Reference Safety Information based on post-marketing pharmacovigilance signals.
Knowledge check
Which public regulatory document provides the most detailed, unvarnished insight into the statistical and clinical concerns raised by FDA reviewers during NDA evaluation?
A The US Package Insert (USPI)
B The FDA Multidisciplinary Review (Medical & Statistical Review) on Drugs@FDA
C The sponsor\'s corporate press release
D The ClinicalTrials.gov study result table
Production drill
A sponsor is planning to file an sNDA (supplemental NDA) to expand the indication of an approved oral JAK inhibitor from Rheumatoid Arthritis to Atopic Dermatitis. Outline three specific regulatory intelligence checks you would perform in Drugs@FDA and EMA EPARs before drafting the Module 2.5 Clinical Overview.
Regulatory Intelligence Search Plan:
1. Competitor Precedent Approvals in Atopic Dermatitis: Inspect the FDA Multi-Disciplinary Reviews and EMA EPARs for recently approved JAK inhibitors (e.g., Upadacitinib, Abrocitinib) to determine the exact co-primary endpoints accepted (EASI-75 and vIGA-AD 0/1 at Week 16) and validated non-responder imputation methods required.
2. Class Safety Warnings & AdComms: Review the FDA Drug Safety Communications and Advisory Committee transcripts regarding class warnings for major adverse cardiovascular events (MACE), thrombosis/DVT, and malignancies with JAK inhibitors to ensure our Module 2.7.4 Safety Summary proactively addresses these specific adverse events of special interest (AESIs).
3. Dose-Optimization Review: Check reviewer comments on whether a step-down dosing strategy or lower starting dose was mandated for pediatric/adolescent age subsets or patients with renal impairment.
Module 4.2 complete
Mapping professional domains & industry transition blueprint
Week 4 · Module 3
Mapping Professional Domains & Industry Transition Blueprint
Navigating medical writing roles across Pharma, Biotech, CROs, MedComms, and Health Authorities
You are a post-graduate in Life Sciences / Pharmacy (M.Sc., M.Pharm, Pharm.D, Ph.D., MBBS) applying for your first industry role as a Regulatory Medical Writer. In the technical round, the hiring director asks: “How would you prioritize your quality control (QC) checks when cross-referencing an integrated summary of safety (ISS) against multiple legacy CSRs, and how do you handle discrepancies in MedDRA coding versions?” Candidates with only generic writing knowledge fail here. This module equips you with the exact domain competencies, terminology, and execution frameworks expected in global industry teams.
The Medical Writing Ecosystem: Core Functional Domains
Medical writing is not a monolithic role. In the biopharmaceutical and clinical research industry, medical writing functions are organized into four major pillars, each requiring distinct regulatory knowledge, technical writing skills, and stakeholder interfaces:
Organizational Architecture Medical Writing Functions Across Industry
EU MDR 2017/745 (Annex XIV/XV), MDCG Guidances, MEDDEV 2.7/1 Rev 4, FDA 21 CFR 820.
Bridging the Gap: Academic Writing vs. Industry Regulatory Writing
Post-graduates transitioning into industry must unlearn academic habits and master the three foundational rules of regulatory writing:
1. Traceability & 100% Data Verifiability: In academia, claims are supported by subjective narrative. In regulatory writing, every single number, percentage, p-value, and confidence interval in the text must be mathematically reconciled against the locked SAP and validated TFL shells (SDTM/ADaM).
2. Active, Lean, Pyramid Structure: Lead with the primary conclusion, followed by supporting statistical evidence and context. Avoid speculative adjectives ("remarkably effective", "promising trend"); use objective, non-interpretative language ("statistically significant reduction in HbA1c [treatment difference -0.72%, 95% CI -0.91 to -0.53, p < 0.001]").
3. Cross-Functional Negotiation: A regulatory writer is the project manager of the dossier. You coordinate clinical, statistical, pharmacokinetic, and regulatory inputs, driving consensus during team comment resolution meetings (CRMs) while strictly defending timeline milestones.
Self-Assessment Drill 4.3.1 · Document Ownership
A sponsor is preparing an aggregate annual safety update for an investigational monoclonal antibody in Phase III trials across the US, EU, and Japan. Which document must be prepared, and what regulatory guideline governs its structure?
A. Periodic Safety Update Report (PSUR) governed by ICH E2C(R2)
B. Development Safety Update Report (DSUR) governed by ICH E2F
C. Investigator's Brochure (IB) governed by ICH E6 Section 7
D. EU Risk Management Plan (EU-RMP) governed by GVP Module V
Module 4.3 complete
Capstone: full global regulatory dossier strategy
Week 3 · Module 3 · Capstone
Capstone: Mapping Your Pathway
Connecting the regulatory landscape to the seven professional domains of medical writing
15 min0 quizzes1 drill
Bridge module
This course has given you a map of regulatory authorities, the development lifecycle, the CTD, key ICH guidelines, pharmacovigilance vocabulary, device regulation, regional variation, and document quality practices. This final module connects that map to the seven professional domains you may choose to specialise in — so that everything you have learned has a place to land.
Regulatory landscape by professional domain
Domain 1 — Publications: ICMJE authorship and reporting standards, journal submission processes, clinical trial registries, and reporting guidelines (such as CONSORT and PRISMA).
Domain 2 — Regulatory: The CTD, Clinical Study Reports, the Investigator's Brochure, and the clinical protocol — the core regulatory documents this course has focused on most directly.
Domain 4 — Medical Information: The SmPC/USPI label, Standard Response Documents, and the governance of off-label information requests.
Domain 5 — Medical Affairs: Materials for Medical Science Liaisons, advisory board documentation, and scientific platform development.
Domain 6 — Medical Devices: EU MDR, Clinical Evaluation Reports, 510(k) submissions, and device clinical investigations.
Domain 7 — HEOR: HTA dossiers, evidence synthesis, and country-specific bodies such as NICE (UK), IQWiG (Germany), and the AMNOG process (Germany).
What comes next
This course was designed to help you recognise terms and locate documents within the regulatory landscape — not to teach you how to author them. Each professional domain listed above has its own dedicated authoring course, where you will learn to actually write the documents you can now recognise and place.
Capstone drill
For your chosen professional domain, list the five most important documents or regulatory frameworks from this course that you will encounter, and describe how you will use the regulatory landscape knowledge in that pathway.
Example (Domain 2 — Regulatory): 1. The CTD structure, especially Module 2 and Module 5, since these are the documents I will draft or contribute to most often. 2. ICH E3, as the primary structural reference every time I am assigned a CSR. 3. The development lifecycle map, so I always know which document is expected at which stage of a project. 4. Knowledge of FDA vs EMA review processes, so I can anticipate regional formatting and content differences on global submissions. 5. Document lifecycle and QC practices, so my drafts move through review efficiently and are inspection-ready.
I will use this landscape knowledge to orient myself quickly on any new project — recognising what a document is, who will read it, and what stage of development it belongs to — before I ever open the authoring-level course for that domain.
Final reflection
Based on your regulatory landscape knowledge, which domain pathway interests you most? Which regulatory documents from this course will be central to your daily work in that pathway?
There is no single correct answer — the goal is to leave this course with a clear sense of where you want to go next.
All modules complete
Regulatory Landscape for Medical Writers
IMRAD Academy · Read like a scientist. Write like a professional. · Home